Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Grouping of Genetic Risk By the European Leukemia Net Classification Predicts Overall Survival and Relapse Incidence in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation

Philipp G. Hemmati, MD, Theis Terwey, MD, Il-Kang Na, MD, Christian Jehn, MD, Lam G. Vuong, PhD, Philipp le Coutre, MD, Bernd Dörken, MD, Renate Arnold, MD

Blood (2015) 126 (23): 2012.

https://doi.org/10.1182/blood.V126.23.2012.2012

Published: 2015

Journal Articles

Achieving Early Remission By Induction Therapy Predicts a Favorable Outcome in Patients with Acute Myeloid Leukemia and an Intermediate Risk Karyotype Undergoing Allogeneic Stem Cell Transplantation in First Complete Remission

Philipp G. Hemmati, MD, Theis H. Terwey, MD, Il-Kang Na, MD, Philipp le Coutre, MD, Christian F. Jehn, MD, Lam G. Vuong, PhD, Bernd Dörken, MD, Renate Arnold, MD

Blood (2014) 124 (21): 2569.

https://doi.org/10.1182/blood.V124.21.2569.2569

Published: 2014

Journal Articles

Impact of Early Blast Clearance Following Induction Chemotherapy On the Outcome of Patients with Acute Myelod Leukemia Undergoing Allogeneic Stem Cell Transplantation in First Complete Remission

Philipp G. Hemmati, MD, Theis H. Terwey, MD, Philipp le Coutre, MD, Gero Massenkeil, MD, Bernd Dörken, MD, Renate Arnold, MD

Blood (2012) 120 (21): 1998.

https://doi.org/10.1182/blood.V120.21.1998.1998

Published: 2012

Journal Articles

Allogeneic Stem Cell Transplantation for Secondary or Therapy-Related Acute Myeloid Leukemia or Myelodysplastic Syndrome with Poor-Risk Cytogenetics.

Philipp G. Hemmati, MD, Theis Terwey, MD, Philipp D. le Coutre, MD, Gero Massenkeil, MD, Lam G Vuong, MD, PhD, Bernd Dörken, MD, Renate Arnold, MD

Blood (2010) 116 (21): 3470.

https://doi.org/10.1182/blood.V116.21.3470.3470

Published: 2010

Journal Articles

Pre-Transplant Risk-Assessment for Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplants.

Philipp G. Hemmati, MD, Theis H. Terwey, MD, Philipp le Coutre, MD, Gero Massenkeil, MD, Lam G Vuong, PhD, Christian Jakob, MD, Arturo Vega, MD, Bernd Dörken, MD, Renate Arnold, MD

Blood (2009) 114 (22): 2302.

https://doi.org/10.1182/blood.V114.22.2302.2302

Published: 2009

Journal Articles

Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning (RIC) Is Effective for Long-Term Disease Control in High-Risk AML Patients in First Complete Remission.

Philipp G. Hemmati, MD, Gero Massenkeil, MD, Theis H. Terwey, MD, Stefan Neuburger, MD, Philipp le Coutre, MD, Lam Vuong, MD, Bernd Dorken, MD, Renate Arnold, MD

Blood (2007) 110 (11): 3020.

https://doi.org/10.1182/blood.V110.11.3020.3020

Published: 2007

NARROW

Grouping of Genetic Risk By the European Leukemia Net Classification Predicts Overall Survival and Relapse Incidence in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation

Achieving Early Remission By Induction Therapy Predicts a Favorable Outcome in Patients with Acute Myeloid Leukemia and an Intermediate Risk Karyotype Undergoing Allogeneic Stem Cell Transplantation in First Complete Remission

Impact of Early Blast Clearance Following Induction Chemotherapy On the Outcome of Patients with Acute Myelod Leukemia Undergoing Allogeneic Stem Cell Transplantation in First Complete Remission

Allogeneic Stem Cell Transplantation for Secondary or Therapy-Related Acute Myeloid Leukemia or Myelodysplastic Syndrome with Poor-Risk Cytogenetics.

Pre-Transplant Risk-Assessment for Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplants.

Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning (RIC) Is Effective for Long-Term Disease Control in High-Risk AML Patients in First Complete Remission.

Email alerts

ASH Publications

American Society of Hematology

Grouping of Genetic Risk By the European Leukemia Net Classification Predicts Overall Survival and Relapse Incidence in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation

Achieving Early Remission By Induction Therapy Predicts a Favorable Outcome in Patients with Acute Myeloid Leukemia and an Intermediate Risk Karyotype Undergoing Allogeneic Stem Cell Transplantation in First Complete Remission

Impact of Early Blast Clearance Following Induction Chemotherapy On the Outcome of Patients with Acute Myelod Leukemia Undergoing Allogeneic Stem Cell Transplantation in First Complete Remission

Allogeneic Stem Cell Transplantation for Secondary or Therapy-Related Acute Myeloid Leukemia or Myelodysplastic Syndrome with Poor-Risk Cytogenetics.

Pre-Transplant Risk-Assessment for Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplants.

Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning (RIC) Is Effective for Long-Term Disease Control in High-Risk AML Patients in First Complete Remission.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only